What This Means for Investors The recent forecast revision for GLP-1 drugs positions Eli Lilly favorably in a growing market, supported by its strong GF Score of 98/100
Additionally, the FDA says Novo Nordisk failed to develop written procedures for reporting postmarketing adverse drug experiences (ADEs)
Holt MK, Cook DR, Brierley DI, Richards JE, Reimann F, Gourine AV, Marina N, Trapp S
Pack your medication in your insulated travel case with fresh gel packs from the cabin fridge
The goal is to enhance, not replace, that system
clinical studies are pending